NASDAQ · Health care

Lipocine Inc. (LPCN)

Lipocine Inc. brought in $1.6M of revenue over the twelve months to June 30, 2026. It posted a net loss of $11.9M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.

Price

$2.10

+0.48% on the day · September 25, 2026

52-week range $1.81 to $12.37

Market cap

$17.3M

Revenue (last 12 months)

$1.6M

Net margin

-755.1%

What Lipocine Inc. does

Lipocine Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LPCN.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$2M	-$10.4M	-$9.6M	-$1.69	n/a
2024	$11.2M	-$1.2M	$8.4K	n/a	-$1.3M
2023	-$2.9M	-$17.9M	-$16.4M	-$3.14	-$11.9M
2022	$500K	-$12.1M	-$10.8M	-$2.15	-$12.1M
2021	$16.1M	$3.1M	-$634.4K	-$0.17	-$4.4M
2020	$0	-$18M	-$21M	-$6.28	n/a

Next report expected around October 1, 2026.

Estimated from its filing rhythm: about 58 days after its last report of August 4, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where LPCN ranks in Health care

Revenue$2M

#547 of 646 in Health care · Bottom 15%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Lipocine Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 16, 2026
Other event 8-K
September 14, 2026
Other event 8-K
September 11, 2026
Other event 8-K
September 10, 2026
Other event 8-K
August 21, 2026
Executive or director change 8-K/A
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 4, 2026
Quarterly results 8-K
August 4, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 69% to $190.1K versus the same quarter last year; diluted EPS -$0.32 versus -$0.41.
August 3, 2026
Executive or director change 8-K
June 12, 2026
Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 7, 2026. Insider transactions on SEC

Insider trades

What the people running Lipocine Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns LPCN

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Squadron Master Fund LP13G, passive with 3 related filers	9.8%	810,000	August 14, 2026
Ikarian Capital, LLC13G, passive with 1 related filers	6.3%	508,556	May 15, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about LPCN

What does Lipocine Inc. do?

Lipocine Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LPCN.

Is Lipocine Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $11.9M on revenue of $1.6M.

How much revenue does Lipocine Inc. make?

Over the twelve months to June 30, 2026 Lipocine Inc. reported revenue of $1.6M.

When did Lipocine Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 16, 2026.

Similar companies

Compare LPCN with

Compare LPCN with any company

Follow LPCN

Get an email when Lipocine Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow LPCN: get an email when it files

Where the numbers come from

Financial figures are the values Lipocine Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.